nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

14.08.2018 | Original Article

Differences in gray and white matter ¹⁸F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias

verfasst von: Hye Joo Son, Jungsu S. Oh, Jee Hoon Roh, Sang Won Seo, Minyoung Oh, Sang Ju Lee, Seung Jun Oh, Jae Seung Kim

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the regional distribution of ¹⁸F-THK5351 uptake in gray (GM) and white matter (WM) in patients with behavioral-variant frontotemporal dementia (bvFTD) and compared it with that in patients with Alzheimer’s disease (AD) or semantic dementia (SD).

Methods

¹⁸F-THK-5351 positron emission tomography (PET), ¹⁸F-florbetaben PET, magnetic resonance imaging, and neuropsychological testing were performed in 103 subjects including 30, 24, 9, and 8 patients with mild cognitive impairment, AD, bvFTD, and SD, respectively, and 32 normal subjects. Standardized uptake value ratios (SUVRs) of ¹⁸F-THK-5351 PET images were measured from six GM and WM regions using cerebellar GM as reference. GM and WM SUVRs and WM/GM ratios, the relationship between GM SUVR and WM/GM ratio, and correlation between SUVR and cognitive function were compared.

Results

In AD, both parietal GM (p < 0.001) and WM (p < 0.001) SUVRs were higher than in bvFTD. In AD and SD, the WM/GM ratio decreased as the GM SUVR increased, regardless of lobar region. In AD, memory function correlated with parietal GM (ρ = −0.74, p < 0.001) and WM (ρ = −0.53, p < 0.001) SUVR. In SD, language function correlated with temporal GM SUVR (ρ = −0.69, p = 0.006). The frontal WM SUVR was higher in bvFTD than in AD (p = 0.003) or SD (p = 0.017). The frontal WM/GM ratio was higher in bvFTD than in AD (p < 0.001). In bvFTD, the WM/GM ratio increased more prominently than the GM SUVR only in the frontal lobe (R² = 0.026). In bvFTD, executive function correlated with frontal WM SUVR (ρ = −0.64, p = 0.014).

Conclusions

Frontal WM ¹⁸F-THK5351 uptake was higher in bvFTD than in other dementias. The increase in frontal WM uptake was greater than the increase in GM uptake and correlated with executive function. This suggests that frontal lobe WM ¹⁸F-THK5351 uptake reflects neuropathological differences between bvFTD and other dementias.

Nur mit Berechtigung zugänglich

Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci. 2007;8:663–72. https://doi.org/10.1038/nrn2194.CrossRefPubMed

Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–54.CrossRefPubMed

Siri S, Benaglio I, Frigerio A, Binetti G, Cappa SF. A brief neuropsychological assessment for the differential diagnosis between frontotemporal dementia and Alzheimer’s disease. Eur J Neurol. 2001;8:125–32.CrossRefPubMed

Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer disease centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266–73. https://doi.org/10.1097/NEN.0b013e31824b211b.CrossRefPubMed

Ossenkoppele R, Pijnenburg YA, Perry DC, Cohn-Sheehy BI, Scheltens NM, Vogel JW, et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138:2732–49. https://doi.org/10.1093/brain/awv191.CrossRefPubMedPubMedCentral

Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034–42. https://doi.org/10.1212/WNL.0b013e31823b9c5e.CrossRefPubMedPubMedCentral

Borroni B, Brambati SM, Agosti C, Gipponi S, Bellelli G, Gasparotti R, et al. Evidence of white matter changes on diffusion tensor imaging in frontotemporal dementia. Arch Neurol. 2007;64:246–51. https://doi.org/10.1001/archneur.64.2.246.CrossRefPubMed

Taipa R, Brochado P, Robinson A, Reis I, Costa P, Mann DM, et al. Patterns of microglial cell activation in Alzheimer disease and frontotemporal lobar degeneration. Neurodegener Dis. 2017;17:145–54. https://doi.org/10.1159/000457127.CrossRefPubMed

Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14:463–77. https://doi.org/10.1038/nri3705.CrossRefPubMed

10.

Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener. 2017;12:50. https://doi.org/10.1186/s13024-017-0192-x.CrossRefPubMedPubMedCentral

11.

Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD, et al. Characterization of tau positron emission tomography tracer [(18)F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016;12:1116–24. https://doi.org/10.1016/j.jalz.2016.01.003.CrossRefPubMed

12.

Harada R, Okamura N, Furumoto S, Furukawa K, Ishiki A, Tomita N, et al. 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med. 2016;57:208–14. https://doi.org/10.2967/jnumed.115.164848.CrossRefPubMed

13.

Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, et al. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9:25. https://doi.org/10.1186/s13195-017-0253-y.CrossRefPubMedPubMedCentral

14.

Harada R, Ishiki A, Kai H, Sato N, Furukawa K, Furumoto S, et al. Correlations of (18)F-THK5351 PET with post-mortem burden of tau and astrogliosis in Alzheimer’s disease. J Nucl Med. 2017. https://doi.org/10.2967/jnumed.117.197426.

15.

Kang Y, Na DL, Hahn S. Seoul Neuropsychological Screening Battery. Incheon: Human Brain Research & Consulting Co.; 2003.

16.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentral

17.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr. 1997;9(Suppl 1):65–9.CrossRefPubMed

18.

Knopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR, Mendez MF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. 2008;131:2957–68. https://doi.org/10.1093/brain/awn234.CrossRefPubMedPubMedCentral

19.

Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2011;38:1104–19. https://doi.org/10.1007/s00259-011-1745-9.CrossRefPubMed

20.

Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67. https://doi.org/10.1093/brain/aww027.CrossRefPubMedPubMedCentral

21.

Schofield E, Kersaitis C, Shepherd CE, Kril JJ, Halliday GM. Severity of gliosis in Pick’s disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain. 2003;126:827–40.CrossRefPubMed

22.

Shi J, Shaw CL, Du Plessis D, Richardson AM, Bailey KL, Julien C, et al. Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. Acta Neuropathol. 2005;110:501–12. https://doi.org/10.1007/s00401-005-1079-4.CrossRefPubMed

23.

Serrano-Pozo A, Mielke ML, Gomez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer’s disease. Am J Pathol. 2011;179:1373–84. https://doi.org/10.1016/j.ajpath.2011.05.047.CrossRefPubMedPubMedCentral

24.

Lu PH, Lee GJ, Shapira J, Jimenez E, Mather MJ, Thompson PM, et al. Regional differences in white matter breakdown between frontotemporal dementia and early-onset Alzheimer’s disease. J Alzheimers Dis. 2014;39:261–9. https://doi.org/10.3233/JAD-131481.CrossRefPubMedPubMedCentral

25.

Zhang Y, Schuff N, Du AT, Rosen HJ, Kramer JH, Gorno-Tempini ML, et al. White matter damage in frontotemporal dementia and Alzheimer’s disease measured by diffusion MRI. Brain. 2009;132:2579–92. https://doi.org/10.1093/brain/awp071.CrossRefPubMedPubMedCentral

26.

Hardy J, Revesz T. The spread of neurodegenerative disease. N Engl J Med. 2012;366:2126–8. https://doi.org/10.1056/NEJMcibr1202401.CrossRefPubMed

27.

Tartaglia MC, Zhang Y, Racine C, Laluz V, Neuhaus J, Chao L, et al. Executive dysfunction in frontotemporal dementia is related to abnormalities in frontal white matter tracts. J Neurol. 2012;259:1071–80. https://doi.org/10.1007/s00415-011-6300-x.CrossRefPubMed

28.

Avants BB, Cook PA, Ungar L, Gee JC, Grossman M. Dementia induces correlated reductions in white matter integrity and cortical thickness: a multivariate neuroimaging study with sparse canonical correlation analysis. NeuroImage. 2010;50:1004–16. https://doi.org/10.1016/j.neuroimage.2010.01.041.CrossRefPubMed

29.

Fowler JS, Volkow ND, Wang GJ, Logan J, Pappas N, Shea C, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431–5.CrossRefPubMed

30.

Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain. 2010;133:300–6. https://doi.org/10.1093/brain/awp248.CrossRefPubMed

31.

Spinelli EG, Mandelli ML, Miller ZA, Santos-Santos MA, Wilson SM, Agosta F, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol. 2017;81:430–43. https://doi.org/10.1002/ana.24885.CrossRefPubMedPubMedCentral

32.

Josephs KA, Hodges JR, Snowden JS, Mackenzie IR, Neumann M, Mann DM, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122:137–53. https://doi.org/10.1007/s00401-011-0839-6.CrossRefPubMedPubMedCentral

33.

Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 2014;127:423–39. https://doi.org/10.1007/s00401-013-1238-y.CrossRefPubMedPubMedCentral

34.

Lee H, Seo S, Lee SY, Jeong HJ, Woo SH, Lee KM, et al. [¹⁸F]-THK5351 PET imaging in patients with semantic variant primary progressive aphasia. Alzheimer Dis Assoc Disord. 2018;32(1):62–9. https://doi.org/10.1097/wad.0000000000000216.CrossRefPubMed

35.

Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer TD, et al. [(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2017. https://doi.org/10.1136/jnnp-2017-316402.

36.

Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5–22. https://doi.org/10.1007/s00401-007-0237-2.CrossRefPubMedPubMedCentral

37.

Downey LE, Mahoney CJ, Buckley AH, Golden HL, Henley SM, Schmitz N, et al. White matter tract signatures of impaired social cognition in frontotemporal lobar degeneration. Neuroimage Clin. 2015;8:640–51. https://doi.org/10.1016/j.nicl.2015.06.005.CrossRefPubMedPubMedCentral

38.

Zhou J, Greicius MD, Gennatas ED, Growdon ME, Jang JY, Rabinovici GD, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer’s disease. Brain. 2010;133:1352–67.CrossRefPubMedPubMedCentral

39.

Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007;27:2349–56. https://doi.org/10.1523/JNEUROSCI.5587-06.2007.CrossRefPubMedPubMedCentral

40.

Spina S, Schonhaut DR, Boeve BF, Seeley WW, Ossenkoppele R, O’Neil JP, et al. Frontotemporal dementia with the V337M MAPT mutation: tau-PET and pathology correlations. Neurology. 2017;88(8):758–66. https://doi.org/10.1212/wnl.0000000000003636.CrossRefPubMedPubMedCentral

41.

Jang YK, Lyoo CH, Park S, Oh SJ, Cho H, Oh M, et al. Head to head comparison of [¹⁸F] AV-1451 and [¹⁸F] THK5351 for tau imaging in Alzheimer’s disease and frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2018;45(3):432–42. https://doi.org/10.1007/s00259-017-3876-0.CrossRefPubMed

Titel: Differences in gray and white matter 18F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias
verfasst von: Hye Joo Son
Jungsu S. Oh
Jee Hoon Roh
Sang Won Seo
Minyoung Oh
Sang Ju Lee
Seung Jun Oh
Jae Seung Kim
Publikationsdatum: 14.08.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4125-x

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Differences in gray and white matter ¹⁸F-THK5351 uptake between behavioral-variant frontotemporal dementia and other dementias

Abstract

Purpose

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Dynamic whole-body PET imaging: principles, potentials and applications

Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes

18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice

Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer

18F-FDG PET/CT diagnostic performance in solitary and multiple pulmonary nodules detected in patients with previous cancer history: reports of 182 nodules

Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PET